UPDATE: H.C. Wainwright On Nektar Therapeutics Notes 'reasons to be cautious on this dataset include:'

‘(1) sample size of 41, of which three have been excluded from analysis for a variety of reasons as disclosed previously; and (2) patients had healthier baseline characteristics than historical studies, for

Benzinga · 11/11/2019 16:56

‘(1) sample size of 41, of which three have been excluded from analysis for a variety of reasons as disclosed previously; and (2) patients had healthier baseline characteristics than historical studies, for example, based on the five-year follow up of the CheckMate-067 program, LDH levels and M1c status were inversely correlated with outcomes’

 

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com